Anthropic launches autonomous drug discovery program with six biopharma partners

On October 28, Anthropic announced that its life sciences team has formed deep research collaborations with six drug discovery organizations, including Bristol Myers Squibb and Generate Biomedicines, and launched an autonomous drug discovery program. The first focus is a rare childhood muscular dystrophy, with Claude, Anthropic's AI model, handling most of the scientific and operational work.

Anthropic is a company focused on AI model development, and Claude is its AI model series. Under the collaboration, Claude will be involved in the research and operational aspects of the drug discovery program. Anthropic's life sciences team will work with the six partner organizations on the project.

Following the announcement, AI drug-discovery related A-share stocks rebounded in morning trading, with Baipusite rising over 10% and several other stocks gaining more than 5%.